iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.84 Billion KRW | -21.36% |
| 2022 | 9.97 Billion KRW | -8.59% |
| 2021 | 10.91 Billion KRW | 8.81% |
| 2020 | 10.03 Billion KRW | 26.74% |
| 2019 | 7.91 Billion KRW | -30.14% |
| 2018 | 11.32 Billion KRW | 12.72% |
| 2017 | 10.05 Billion KRW | 76.91% |
| 2016 | 5.68 Billion KRW | -3.77% |
| 2015 | 5.9 Billion KRW | 0.0% |
| 2012 | 4.75 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.84 Billion KRW | -25.04% |
| 2024 Q2 | 2 Billion KRW | 8.82% |
| 2023 FY | 7.84 Billion KRW | -21.36% |
| 2023 Q3 | 1.17 Billion KRW | -39.89% |
| 2023 Q4 | 2.45 Billion KRW | 108.49% |
| 2023 Q2 | 1.96 Billion KRW | -17.45% |
| 2023 Q1 | 2.37 Billion KRW | 4.75% |
| 2022 Q3 | 2.02 Billion KRW | -34.73% |
| 2022 FY | 9.97 Billion KRW | -8.59% |
| 2022 Q4 | 2.26 Billion KRW | 12.01% |
| 2022 Q2 | 3.1 Billion KRW | 19.89% |
| 2022 Q1 | 2.58 Billion KRW | 29.88% |
| 2021 Q1 | 2.81 Billion KRW | 19.16% |
| 2021 FY | 10.91 Billion KRW | 8.81% |
| 2021 Q4 | 1.99 Billion KRW | -20.33% |
| 2021 Q2 | 3.7 Billion KRW | 31.39% |
| 2021 Q3 | 2.49 Billion KRW | -32.51% |
| 2020 Q3 | 70.2 Million KRW | -98.35% |
| 2020 FY | 10.03 Billion KRW | 26.74% |
| 2020 Q4 | 2.36 Billion KRW | 3269.46% |
| 2020 Q1 | 2.28 Billion KRW | 6.11% |
| 2020 Q2 | 4.24 Billion KRW | 85.9% |
| 2019 FY | 7.91 Billion KRW | -30.14% |
| 2019 Q4 | 2.15 Billion KRW | -39.1% |
| 2019 Q3 | 3.53 Billion KRW | 113.25% |
| 2019 Q2 | 1.65 Billion KRW | 15.0% |
| 2019 Q1 | 1.44 Billion KRW | -53.5% |
| 2018 FY | 11.32 Billion KRW | 12.72% |
| 2018 Q2 | 3.24 Billion KRW | 31.28% |
| 2018 Q1 | 2.47 Billion KRW | -57.96% |
| 2018 Q3 | 5.5 Billion KRW | 69.68% |
| 2018 Q4 | 3.09 Billion KRW | -43.7% |
| 2017 Q1 | 1.49 Billion KRW | -56.41% |
| 2017 FY | 10.05 Billion KRW | 76.91% |
| 2017 Q4 | 5.87 Billion KRW | 211.96% |
| 2017 Q3 | 1.88 Billion KRW | -61.09% |
| 2017 Q2 | 4.84 Billion KRW | 223.73% |
| 2016 FY | 5.68 Billion KRW | -3.77% |
| 2016 Q4 | 3.43 Billion KRW | 122.16% |
| 2016 Q3 | 1.54 Billion KRW | 1.02% |
| 2016 Q2 | 1.52 Billion KRW | 3.49% |
| 2016 Q1 | 1.47 Billion KRW | 0.0% |
| 2015 FY | 5.9 Billion KRW | 0.0% |
| 2013 Q3 | 1.02 Billion KRW | -6.1% |
| 2013 Q2 | 1.09 Billion KRW | 8.89% |
| 2013 Q1 | 1 Billion KRW | -11.29% |
| 2012 FY | 4.75 Billion KRW | 0.0% |
| 2012 Q4 | 1.13 Billion KRW | -0.06% |
| 2012 Q3 | 1.13 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 92.867% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 85.908% |
| Bioneer Corporation | 204.55 Billion KRW | 96.165% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -1.365% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 87.988% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | 75.762% |
| Helixmith Co., Ltd | 37.36 Billion KRW | 79.003% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 97.256% |
| Medy-Tox Inc. | 110.88 Billion KRW | 92.924% |
| Peptron, Inc. | 16.65 Billion KRW | 52.897% |
| Amicogen, Inc. | 52.82 Billion KRW | 85.147% |
| Genexine, Inc. | 41.62 Billion KRW | 81.153% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | 51.469% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 92.044% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 80.834% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 91.228% |
| SillaJen, Inc. | 5.11 Billion KRW | -53.471% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | 69.429% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | 77.742% |
| Genomictree Inc. | 16.26 Billion KRW | 51.762% |
| MedPacto, Inc. | 26.91 Billion KRW | 70.854% |
| D&D Pharmatech | 32.16 Billion KRW | 75.606% |
| EASY BIO,Inc. | 29.67 Billion KRW | 73.558% |
| GI Innovation, Inc. | 57.59 Billion KRW | 86.377% |